Vivus to Try Again By Year’s End

Vivus (NASDAQ: VVUS), the Mountain View, CA-based developer of an obesity drug, said today it hopes to resubmit its new drug application to the FDA for phentermine and topiramate (Qnexa) by the end of the year. The first application from Vivus was shot down by the FDA in October, when the FDA asked for an assessment of whether the drug was linked to any increased risk of miscarriages or birth defects. The company, after meeting with the FDA to discuss its concerns, offered more information in January about how the agency was looking for increased risks of oral clefts, or cleft palates in newborns from women who got one of the key ingredients in the Vivus weight loss drug.

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

One response to “Vivus to Try Again By Year’s End”

  1. zoom says:

    The scumsuckers at the FDA should be ashamed of themselves. Oral clefts? Really? Exactly how many women diet during their pregnancy? It’s hard to find any drug without serious side effects; that’s why they put warnings on medications.

    F**king fda scumbags; if I had my way, I would take their entire department, and catapult it into the sun.